Dr. Reddy's unveils generic Ciprodex

Dr. Reddy’s is releasing the first generic of Bayer's Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) otic suspension. The drug is indicated to treat acute otitis media in pediatric patients with ear types, and acute otitis externa in children, adults and elderly patients. 

“We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients,” said Marc Kikuchi, Dr. Reddy's CEO of North America generics. “At the same time, this product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form.”

The Ciprodex brand had a market value of approximately $453 million for the most recent 12 months ended June 2020, according to IQVIA.

Dr. Reddy’s ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, is available as 7.5 ml fill in a 10 ml bottle.